Medical Cannabis. Danial Schecter, MD, CCFP. Vocational Rehabilitation Association November 7th, Executive Director Cannabinoid Medical Clinic

Similar documents
Use of Cannabinoids in Medical Practice

POLICY NUMBER: POL 153

Acknowledgements: What it is What it s not. Cannabis Evidence Series. Evidence-informed decision-making

Marijuana and Adolescents: Truth and Consequences. Disclosure Statement OBJECTIVES. Secondary Objectives. State of Marijuana in US

The Cannabis model in Canada and the USA. Dr Mark A Ware MD MRCP MSc McGill University Montreal, Quebec, Canada

Medicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer

CBD and Your Health.

Research: Medical Cannabis

Medical Marijuana. Navigating Medical Marijuana in Workers Compensation

Medical Cannabinoids for the Management of Chronic Noncancer Pain

The Effects known & unknown of Marijuana in Older Adults. Danielle Fixen, PharmD, BCGP, BCPS University of Colorado School of Pharmacy

Medical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center. Disclosure.

Curious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD

Objectives. 1. Review controversy 2. Pathophysiology 3. Indications for Use 4. Adverse Effects 5. How Patients Access

Cannabinoids: access and symptom management in cancer

Medical Marijuana. Speaker Disclosure Requirements. Share with a Partner 4/10/2015

Cannabis and the Workplace. By Karen Stokke Learning Manager. Stereotypes. Things are changing

Medicinal Marijuana: The Canadian Journey

I would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people

Faculty/Presenter Disclosure

A look at Marijuana in 2014

Medical Marijuana and the Workplace: Human Rights Considerations for ONA Members

The Return of Medicinal Cannabis

Medicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system

Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina) S. Korownyk EDMONTON AB MEDICAL CANNABANOIDS IN PRIMARY CARE

James McCormack BSc (Pharm), PharmD Professor Faculty of Pharmaceutical Sciences University of British Columbia Vancouver, BC, Canada

Medical vs Recreational Use of Cannabis. 11 th December 2017

Medical Cannabis MATT WEBSTER DO, MS

Recent trends in medical cannabis use in Canada

CANADIAN CANNABIS CRAZE (AND CONUNDRUM) Dr. Melissa Snider-Adler Chief Medical Review Officer DriverCheck Inc. Addiction Medicine Physician

Research on Cannabis and PD: Is there any evidence?

MEDICAL MARIJUANA: WHAT S THE EVIDENCE?

Medical Marijuana: The Move to Schedule II

Clinical Education Initiative MEDICAL MARIJUANA 101. Speaker: Patricia Reed, PharmD

Act 16 and Medical Cannabis in Pennsylvania

Reefer Madness version 3.0*

Medical Marihuana for Patients in the Lymphoma Setting. Speakers: Ruth Turner, RN, Con Rob Laister, PhD

MEDICAL CANNABIS IN MINNESOTA

Life s brighter under the sun MEDICAL CANNABIS AND GROUP BENEFITS PLAN COVERAGE

CANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS

Federal Law: Marijuana

use in Canada: What nurses need to know

Explanatory note for Operational Policy Manual (OPM) # , Cannabis for Medical Purposes

MANAGING MEDICAL & RECREATIONAL CANNABIS IN THE WORKPLACE

Outcome. Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C

Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C

9/13/2017. Marijuana and the Brain Matthew Wong, MD Assistant Professor, Department of Neurology, Epilepsy Section. Disclosures.

Medical Cannabis use in the Older Patient

Medical (and Recreational) Marijuana in the Workplace. Jamie LeMesurier, QC Chad Sullivan

Medical Marijuana Consent Form

Dr. Meldon Kahan. Women s College Hospital. with PIA LAW

This questionnaire will ask you about approved medical use of extracts and tinctures of cannabis at national level.

The Evidence. Alex Crawley, BSP, ACPR RxFiles Academic Detailing Program

MARIJUANA in MEDICAL CARE READY or RISKY. HINDI MERMELSTEIN, MD FAPM Beth Israel Medical Center, NYC Dec

Medical Marijuana. Implications for Driving and the Workplace

Medical Cannabis Program. Dr. Maureen Small Co Medical Director Andrea Sundberg Program Coordinator

Learning Objectives 1/8/2019. Therapeutic Potential of the Marijuana-Derived Cannabinoids THC and CBD. Disclosures. Outline. Take home messages

Minnesota Medical Cannabis Program. October 24, 2017

HEALTH WELLNESS COMMUNITY

Marijuana and the Chronic Non-Cancer Pain Patient

Budding Therapies: Medical Cannabis and its Uses

Medical Marijuana in the Workforce. What This Is...And What It Isn t

MEDICAL CANNABIS PATIENT COUNSELING. Krissy Bernazani, RPh Clinical Director Zen Leaf

Use of Medical Marijuana in Cancer Treatment & Care

Dear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE

Agracan - LP. Palmerston Industrial Park Cannabis Cultivation Facility

MEDICAL CANNABIS IN MINNESOTA

Coalition for Medical Marijuana Research & Education

WiFi. Network: Renaissance Conference Password: officeteamfield. Sponsored by:

Consumer Information Cannabis (Marihuana, marijuana)

Virtual Lectures Planning Committee Disclosure Summary

Cannabis and the Endocannabinoid System

Medical Marijuana A Brief Overview of the Program in Ohio and Pharmacology of Cannabinoids

Medical Marijuana A Brief Overview of the Program in Ohio and Pharmacology of Cannabinoids

Clinical Policy Title: Botanical marijuana for medical use

ADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP

MARIHUANA IN THE WORKPLACE

Marijuana and the Workplace : Changing Times

Medical Cannabis use in the Older Patient. Amanjot Sidhu, MD, FRCPC Division of Geriatric Medicine McMaster University

James Donaldson CEO and Executive Director

CANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE

Cannabidiol as a potential treatment for anxiety disorders. Esther Blessing, MD PhD

Clinical Policy Title: Botanical marijuana for medical use

Cannabis and Cannabinoids: Review of Existing and Potential Therapeutic Applications in Oncology

Grants/Research Support: Allergan, Valeant, Lily, Merz Speakers Bureau/Honoraria: Allergan, CCIC/Bayer Consulting Fees: Allergan, Bayer, Biogen

Opioid Review and MAT Clinic Marijuana

LEGALIZED AND MEDICAL MARIJUANA IN THE WORKPLACE

Medicinal Marijuana: Closing the gap between anecdotal benefits and evidence-based research. Jonathan Kiesman, Pharmacist CanniMed Ltd.

Australian Medicinal Cannabis Pricing Analysis

Endocannabinoid System Cannabinoid Drugs


History Of Medical Cannabis

CANNABIS FOR THE RHEUMATOLOGIST

Medical Marijuana: Hype versus Evidence

Cannabis and What we Know. Bonnie Schnittker RN PHN Public Health Nurse October 20, 2017

Medical Cannabis and OMT

Medical Cannabis In the Care of the Elderly

Questionnaire 1 of 5: Cannabis Plant and Cannabis Resin. Introduction

Dr. Hagit Marchaim, Regulatory Affairs & Drug Development Consulting - HMC

Transcription:

Medical Cannabis Danial Schecter, MD, CCFP Executive Director Cannabinoid Medical Clinic Vocational Rehabilitation Association November 7th, 2014

Conflict of Interest This program has not received financial support

Why Cannabinoid Medicine Became aware of the Endocannabinoid System Realization that traditional pharmaceutical agents had limited efficacy or intolerable side effects Listened to stories of patients who achieved real benefit with improved quality of life

My first observational study of Cannabinoids

Learning Objectives Understand why cannabinoids are considered a valid therapeutic choice Become aware of the medical cannabis regulations in Canada Recognize barriers encountered by workers (and employers) of patients who use medical cannabis and re-entering the workforce

The Endocannabinoid System Signaling system (similar to hormones) Important regulatory function in physiologic and pathophysiologic processes including: Neural development Immune function Inflammation Appetite Metabolism and energy homeostasis Cardiovascular function Digestion Bone development and bone density Synaptic plasticity and learning Pain Reproduction Psychiatric disease Psychomotor behavior Memory Wake/sleep cycles Regulation of stress and emotional state

The Endocannabinoid System

Distribution of CB1 Receptors

Pharmacologic action of Phytocannabinoids 9-THC is the only cannabinoid that is psychoactive

Commonly Cited Clinical Indications Chronic neuropathic or musculoskeletal pain Nausea and vomiting due to chemotherapy or HIV treatment Appetite stimulant Hypnotic Anticonvulsant Motor disorder (PD, Huntington, Tourettes) Spasticity due to MS Glaucoma Anxiety, PTSD Autism Other...?

Opioid Sparing Effects of Cannabis Cannabinoids exhibit analgesic effects and may potentiate the antinociceptive effects of opioids Cannabinoids may decrease the amount of opioids required, thereby decreasing negative side-effects

Importance to Vocational Rehabilitation Professionals Currently 40 50 000 people using medical cannabis. Projected to grow to 450 000 people in 10 years.

Cannabinoids in Canada Dronabinol/THC 2.5 10 mg THC (Marinol) Nabilone 0.25 1 mg THC (Cesamet) Nabiximols 2.5 mg THC + 2.5 mg CBD (Sativex) Herbal Cannabis THC < 0.5 % to > 17 % CBD 0 % to 9 % Oral Capsule Start with 2.5 mg qhs and increase up to 10 mg BID Approved for chemotherapy induced nausea and vomiting and anorexia associated with HIV/AIDS Oral capsule Start with 0.5 mg qhs and slowly titrate to 1 mg BID as tolerated Maximum recommended dose is 6 mg/day Same indications as Dronabinol Oromucosal spray Start at 1 spray every 4 hrs to a maximum of 4 sprays on day 1 and increase as tolerated Average dose is 5 sprays/day; limited experience with doses higher than 12 sprays/day Approved for multiple sclerosis associated neuropathic pain and cancer pain Authorized use via Marihuana for Medical Purposes Regulations (MMPR Health Canada) Average 1-2 grams per day (~ 2 4 joints) Not formally approved as a prescription drug (no DIN) Availability and Cost: 2.5 mg capsule: $ 2.05 pd 5.0 mg capsule $ 4.10 No longer available in Canada Availability and cost: 0.25 mg capsule: $ 1.64 pd 0.5 mg capsule $ 3.29 pd 1.0 mg capsule: $ 6.58 pd Available via ODB, no LU code needed Availability and Cost: $ 3-5 per spray Not covered via ODB Availability and Cost: 3 $ - 12 $ per gram Available from Licensed Producers approved by Health Canada No coverage (Veterans Affairs)

Marihuana for Medical Purposes Regulations (MMPR) Effective as of June 2013 and replaced the MMAR regime as of April 1 st 2014 Can only obtain cannabis from a Licensed Producer (LP) Able to access cannabis from an LP with a medical document (prescription) from an authorized health care provider Physician able to prescribe according to his/her judgment/clinical discretion

Licensed Producers License granted by Health Canada Strict quality control measures Tests every lot for contaminants and percentage of THC and CBD Listed on Health Canada s website Only able to sell herbal cannabis, no extracts (tinctures/oils) or edibles Can not have a store-front Only 13 listed on Health Canada s website although 22 approved

Barriers to Re-Entry to the Workplace

Barriers to Re-Entry to the Workplace Stigma associated with disclosure of disability requiring cannabis therapy Until now few medical cannabis users, companies able to have Zero Tolerance! Medical Review Officers (MRO) do not have strict guidelines to deal with lab results US DOT regulated employees not allowed to use cannabis (recreational or medical)

Employer s Responsibilities Become informed about the medical benefits of cannabis Must abide by human rights legislation and the duty to accommodate Develop company policies surrounding the use of potentially psychoactive medications Accommodate employees in safety sensitive positions

Employee Rights and Responsibilities Right to accommodation only if employee reports use of medical cannabis Respect smoking rules and regulations (consider vaporizer and edibles)

Issues to consider when reentering the workplace Does the employee hold a safety sensitive position? May require Independent Medical Assessment by Occupational Health MD Cannabis may not impair the employee may boost productivity

Why can t I find a physician to prescribe me cannabis? Physicians are not obliged to authorize the use of medical marijuana by patients The CMA still believes there is insufficient scientific evidence available to support the use of marijuana for clinical purposes.

Why can t I find a physician to prescribe me cannabis?

Why can t I find a physician to prescribe me cannabis?

Why can t I find a physician to prescribe me cannabis? 10/80/10 Rule No guidelines (conditions/dosage/titration) Smoked/inhaled Fear of abuse Fear of regulatory bodies Repeating mistakes of Oxycontin Time crunch

Cannabinoid Medical Clinic Doors opened July 14, 2014 First clinic seeing patients on a referral basis only No patient fees for ancillary services, no affiliations with specific LPs Focus on: 1) Patient care 2) Physician Education 3) Clinical Research

Cannabinoid Medical Clinic The patient experience: Plan to spend 1-1.5 hours at the clinic Able to complete comprehensive questionnaire at home on proprietary EMR Sees nurse prior to MD, provides education about MMPR, THC:CBD, process Following MD sees a Cannabinoid Educator

Our Cannabinoid Educators Educate patients on safe usage, monitoring, titration and potential side effects Recommend Licensed Producer Helps with paperwork Demonstrate Vaporizers Available for questions

Take Home Messages Medical Cannabis is a valid treatment that is prescribed by physicians Effects of medical cannabis are often different than recreational cannabis Patients often achieve functional improvements that allows return to work Employers have a duty to accommodate Employees in safety sensitive positions may benefit from Independent Medical Evaluation (IME)

Questions